Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in
non cardiac surgery. Previous studies have reported that the total incidence of neurological
pod ranged from 10% to 22%. Dexmedetomidine (DEX) is an a-2 adrenergic agonist for sedation.
This kind of drug has little effect on respiratory function, is easy to wake up and has
analgesic effect. It is a commonly used perioperative adjuvant drug. However, for
neurosurgical patients with brain tumors, the role of DEX in POD is not clear. The purpose of
this study was to investigate the effect of DEX on POD in neurosurgical brain tumor surgery.